Evidence map›Paper›PMID 34797503›Full record

ArticleObesity surgery2022

Gastric Mucosal Devitalization (GMD): Using the Porcine Model to Develop a Novel Endoscopic Bariatric Approach.

Mohamad I Itani, Andreas Oberbach, Kevan J Salimian, Markus Enderle, Hartmut Hahn, Shahem Abbarh, Katherine Kendrick, Nadine Schlichting, Robert A Anders, Sepideh Besharati and 5 more

3 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Obesity surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05486338 nacompletednot on this mapstarted 2023, after this paper: background citation

Endoscopic Gastric Mucosal Ablation (GMA) as a Primary Obesity Therapy Early Feasibility [COMET EF] - Step II

TypeinterventionalSponsorErbe Elektromedizin GmbHRan2023 to 2025Enrolled15ConditionsObesity, AdiposityArmsHybrid Argon Plasma Coagulation (HAPC)
NCT05574777 nacompletednot on this mapstarted 2023, after this paper: background citation

Safety and Feasibility of HybridAPC for Gastric Mucosal Ablation in the Management of Patients With Class III Obesity

TypeinterventionalSponsorErbe Elektromedizin GmbHRan2023 to 2026Enrolled13ConditionsAdiposity, Morbid, ObesityArmsHybrid Argonplasma coagulation (HAPC)
NCT05587491 nacompletednot on this mapstarted 2023, after this paper: background citation

Feasibility and Safety of HybridAPC for Gastric Mucosal Ablation in the Management of Patients With Obesity.

TypeinterventionalSponsorErbe Elektromedizin GmbHRan2023 to 2025Enrolled15ConditionsObesity, AdiposityArmsHybrid Argonplasma coagulation (HAPC)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Mohamad I ItaniDepartment of Internal Medicine, Wayne State University, Detroit, MI, 48201, USA.
Andreas OberbachDepartment of Diagnostics, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Kevan J SalimianDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21287, USA.
Markus EnderleERBE Elektromedizin GmbH, Tübingen, Germany.
Hartmut HahnERBE Elektromedizin GmbH, Tübingen, Germany.
Shahem AbbarhDivision of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, MD, 21287, USA.
Katherine KendrickDivision of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, MD, 21287, USA.
Nadine SchlichtingDepartment of Diagnostics, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Robert A AndersDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21287, USA.
Sepideh BesharatiDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21287, USA.
Jad FarhaDivision of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, MD, 21287, USA.
Lea FayadDivision of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, MD, 21287, USA.
Anthony N KallooDivision of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, MD, 21287, USA.
Dilhana BadurdeenDivision of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, MD, 21287, USA.
Vivek KumbhariDivision of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, MD, 21287, USA. vkumbhari@gmail.com.ORCID 0000-0002-7772-9006
Johns Hopkins University · USErbe Elektromedizin (Germany) · DEFraunhofer Institute for Cell Therapy and Immunology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsAs the pig model has similar gastrointestinal anatomy and physiology to humans, we used pigs to create a gastric mucosal devitalization (GMD) model in preparation for clinical translation of this technique as an endoscopic bariatric therapy (EBT). The aims of this study were to determine the ablation parameters and technique for a successful, safe, and feasible large surface area GMD that produces weight loss.

methodsWe performed GMD using argon plasma coagulation (APC) in 3 phases. Phase 1 assessed the ablation energy required to accomplish selective mucosal ablation using ex vivo pig stomachs (n = 2). Phase 2 assessed the optimal percentage of mucosal surface area to be treated and was performed on 10 pigs. Phase 3 assessed feasibility, efficacy, and safety with 8 pigs randomized into GMD (n = 4) or sham (SH, n = 4) and survived for 1 month. Body weights (GMD, n = 4, SH, n = 4) were measured daily in phase 3 for 1 month, and relative body weights were calculated and analyzed using one-tailed Student's t-test. Percent body fat was compared between GMD and SH at baseline and 1 month post-GMD.

resultsPhase 1 identified the optimal ablation parameters (120 W) that were then used in phase 2. Phase 2 revealed a trend that was suggestive that the optimal percent surface area to ablate was similar to that which is removed at laparoscopic sleeve gastrectomy. In phase 3, GMD was performed over 70% surface area of the greater curvature of the stomach in four pigs. GMD pigs had significantly lower relative body weight increase compared to SH at 1 month (1.375 ± 0.085 vs 1.575 ± 0.047, p = 0.0435). MRI showed a significantly lower body fat mass at 1 month in GMD pigs (5.9 ± 0.4% vs 12.7 ± 2.3%, p = 0.026) compared to SH.

conclusionsGMD resulted in decreased weight gain in the GMD group as evidenced by a lower relative body weight at 1 month. GMD in an animal model appears to show promise as a potential weight loss therapy.

Indexed as

LaparoscopyObesity, MorbidAnimalsGastrectomyGastric MucosaHumansStomachSwineWeight GainWeight LossBariatric therapyGastric mucosal devitalizationPig modelWeight loss

Identifiers

PMID34797503
OpenAlexW3212390725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.